Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
暂无分享,去创建一个
[1] L. Lumeng,et al. Importance of delta opioid receptors in maintaining high alcohol drinking , 1991, Psychopharmacology.
[2] D. Overstreet,et al. Selective inhibition of alcohol intake in diverse alcohol-preferring rat strains by the 5-HT2A antagonists amperozide and FG 5974. , 1997, Alcoholism, clinical and experimental research.
[3] R. Wise,et al. A psychomotor stimulant theory of addiction. , 1987, Psychological review.
[4] M. Dongier,et al. Efficacy of buspirone in alcohol dependence: a review. , 1996, Alcoholism, clinical and experimental research.
[5] F. D. Del Boca,et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. , 1995, The American journal of psychiatry.
[6] L. Parsons,et al. Specific Alterations of Extracellular Endocannabinoid Levels in the Nucleus Accumbens by Ethanol, Heroin, and Cocaine Self-Administration , 2007, Journal of Neuroscience.
[7] R. Spanagel,et al. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. , 1996, European journal of pharmacology.
[8] John B Saunders,et al. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. , 2002, Alcoholism, clinical and experimental research.
[9] S. Nguyen,et al. Topiramate reduces ethanol consumption by C57BL/6 mice , 2007, Synapse.
[10] M. Javors,et al. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker. , 2001, Alcoholism, clinical and experimental research.
[11] R. Hagan,et al. Effect of 5‐HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat , 1990, British journal of pharmacology.
[12] P. de Witte,et al. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. , 2003, Alcoholism, clinical and experimental research.
[13] R. Spanagel,et al. Acamprosate: preclinical data , 2005 .
[14] N. Ait-Daoud,et al. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. , 2000, Alcoholism, clinical and experimental research.
[15] H. Kleber,et al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans , 2002, Psychopharmacology.
[16] C. X. Poulos,et al. The effects of selective blockade of delta and mu opiate receptors on ethanol consumption by C57BL/6 mice in a restricted access paradigm , 1993, Brain Research.
[17] W. Mcbride,et al. Effects of fluoxetine on the intragastric self-administration of ethanol in the alcohol preferring P line of rats. , 1988, Alcohol.
[18] B. Rounsaville,et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. , 1992, Archives of general psychiatry.
[19] G. Koob. Neural Mechanisms of Drug Reinforcement a , 1992, Annals of the New York Academy of Sciences.
[20] F. Petty,et al. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. , 1996, Alcoholism, clinical and experimental research.
[21] H. Samson,et al. Reduction in oral ethanol self-administration in the rat by the 5-HT uptake blocker fluoxetine , 1990, Pharmacology Biochemistry and Behavior.
[22] C. Robert Cloninger,et al. Neurogenetic adaptive mechanisms in alcoholism. , 1987, Science.
[23] R. D. Myers,et al. Differential efficacy of serotonergic drugs FG5974, FG5893, and amperozide in reducing alcohol drinking in P rats. , 1996, Alcohol.
[24] M. Linnoila,et al. Biologic Correlates of Suicidal Risk and Aggressive Behavioral Traits , 1992, Journal of clinical psychopharmacology.
[25] P. Chrétien,et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? , 1984, Pharmacology Biochemistry and Behavior.
[26] K. Wesnes,et al. A Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Acamprosate and Naltrexone , 2002, Neuropsychopharmacology.
[27] K. Gill,et al. Serotonin Uptake Blockers and Voluntary Alcohol Consumption , 1989 .
[28] W. Brink,et al. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics , 2007, European Neuropsychopharmacology.
[29] John H. Krystal,et al. Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking , 2007, Biological Psychiatry.
[30] T. Meert,et al. Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats. , 1991, Pharmacopsychiatry.
[31] A. Alterman,et al. Naltrexone in the treatment of alcohol dependence. , 1992, Archives of general psychiatry.
[32] H. Samson,et al. Effects of acamprosate on ethanol-seeking and self-administration in the rat. , 2001, Alcoholism, clinical and experimental research.
[33] C. Naranjo,et al. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. , 1995, Addiction.
[34] G. Gessa,et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. , 2002, Alcohol and alcoholism.
[35] J. Hensler,et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. , 2000, JAMA.
[36] Trevor Sharp,et al. A review of central 5-HT receptors and their function , 1999, Neuropharmacology.
[37] H. de Wit,et al. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. , 1994, Behavioural pharmacology.
[38] C. Bouza,et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. , 2004, Addiction.
[39] L. Heisler,et al. Fluoxetine Decreases Fat and Protein Intakes But Not Carbohydrate Intake in Male Rats , 1997, Pharmacology Biochemistry and Behavior.
[40] D. Davidson,et al. Naltrexone increases the latency to drink alcohol in social drinkers. , 1996, Alcoholism, clinical and experimental research.
[41] Ting-kai Li,et al. Long and short alcohol deprivation: effects on AA and P alcohol-preferring rats. , 1989, Alcohol.
[42] M. Goldman,et al. Effects of naloxone on ethanol dependence in rats. , 1984, Drug and alcohol dependence.
[43] J. Woods,et al. Noncontingent and response-contingent intravenous ethanol attenuates the effect of naltrexone on hypothalamic-pituitary-adrenal activity in rhesus monkeys. , 2004, Alcoholism, clinical and experimental research.
[44] B. Johnson. Recent Advances in the Development of Treatments for Alcohol and Cocaine Dependence , 2005, CNS drugs.
[45] R. D. Myers,et al. Naltrexone and Amperozide Modify Chocolate and Saccharin Drinking in High Alcohol-Preferring P Rats , 1998, Pharmacology Biochemistry and Behavior.
[46] D. Economidou,et al. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats , 2005, Psychopharmacology.
[47] S. Skradski,et al. Topiramate Blocks Kainate‐Evoked Cobalt Influx into Cultured Neurons , 2000, Epilepsia.
[48] J. Wolffgramm,et al. From controlled drug intake to loss of control: the irreversible development of drug addiction in the rat , 1995, Behavioural Brain Research.
[49] G. Gessa,et al. MDL 72222, a selective 5-HT3 receptor antagonist, suppresses voluntary ethanol consumption in alcohol-preferring rats. , 1991, Alcohol and alcoholism.
[50] Z. Rossetti,et al. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. , 1995, European journal of pharmacology.
[51] M. Thase,et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. , 1997, Archives of general psychiatry.
[52] Jennie Z. Ma,et al. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. , 2006, Addiction.
[53] R. Wurtman,et al. Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats. , 1979, Life sciences.
[54] A. Herz. Endogenous opioid systems and alcohol addiction , 1997, Psychopharmacology.
[55] J. Manzanares,et al. Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects. , 2005, Alcohol and alcoholism.
[56] P. Carlen,et al. Modulation of High‐Voltage–Activated Calcium Channels in Dentate Granule Cells by Topiramate , 2000, Epilepsia.
[57] M. Heilig,et al. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. , 2006, Pharmacology & therapeutics.
[58] R. Wise,et al. Effects of pre-feeding on food-approach latency and food consumption speed in food deprived rats , 1985, Physiology & Behavior.
[59] F. Iber,et al. Disulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study , 1986 .
[60] O. T. Lopez,et al. Serotonin 5-HT3 antagonists fail to affect ethanol self-administration of rats. , 1994, Alcohol.
[61] D. German,et al. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine , 1984, Neuroscience.
[62] I. Geller,et al. Ethanol preference in the hamster: effects of morphine sulfate and naltrexone, a long-acting morphine antagonist. , 1976, Proceedings of the Western Pharmacology Society.
[63] T. Silverstone. Drugs and Appetite , 1982 .
[64] K. Gysling,et al. Morphine-induced activation of A10 dopamine neurons in the rat , 1983, Brain Research.
[65] K. Gill,et al. Treatment with sertraline, a new serotonin uptake inhibitor, reduces voluntary ethanol consumption in rats. , 1988, Alcohol.
[66] C. Hodge,et al. Stimulation of Endorphin Neurotransmission in the Nucleus Accumbens by Ethanol, Cocaine, and Amphetamine , 2001, The Journal of Neuroscience.
[67] R. Moos,et al. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. , 1996, Addiction.
[68] P. Chrétien,et al. Isolation and striatal (3H) serotonin uptake: Role in the voluntary intake of ethanol by rats , 1985, Pharmacology Biochemistry and Behavior.
[69] Rachel A. Millstein,et al. Ethanol-related behaviors in serotonin transporter knockout mice. , 2006, Alcoholism, clinical and experimental research.
[70] K. Hornik,et al. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. , 2004, Drug and alcohol dependence.
[71] R. Spanagel,et al. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. , 1996, European journal of pharmacology.
[72] G. Gessa,et al. Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. , 2000, Alcoholism, clinical and experimental research.
[73] C. Naranjo,et al. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. , 1999, Alcoholism, clinical and experimental research.
[74] C. Naranjo,et al. Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers. , 1989, Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism.
[75] C. Fahlke,et al. Involvement of the serotonergic system in ethanol intake in the rat. , 1993, Alcohol.
[76] W. van den Brink,et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. , 2004, Alcoholism, clinical and experimental research.
[77] B. Rounsaville,et al. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. , 1996, Journal of consulting and clinical psychology.
[78] B. Rounsaville,et al. Experience of a "slip" among alcoholics treated with naltrexone or placebo. , 1996, The American journal of psychiatry.
[79] H. L. Altshuler,et al. Alteration of ethanol self-administration by naltrexone. , 1980, Life sciences.
[80] H. Kranzler,et al. Sustained-release naltrexone for alcoholism treatment: a preliminary study. , 1998, Alcoholism, clinical and experimental research.
[81] W. Millington,et al. Glycyl-glutamine in nucleus accumbens reduces ethanol intake in alcohol preferring (P) rats , 2005, Brain Research.
[82] A T McLellan,et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. , 2000, JAMA.
[83] J. Krystal,et al. NMDA Receptor Antagonism and the Ethanol Intoxication Signal , 2003, Annals of the New York Academy of Sciences.
[84] G. Koob,et al. Effects of amperozide, 8-OH-DPAT, and FG 5974 on operant responding for ethanol , 1998, Psychopharmacology.
[85] R. Spanagel,et al. The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal. , 1996, European journal of pharmacology.
[86] D. Lovinger,et al. Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells. , 1996, The Journal of pharmacology and experimental therapeutics.
[87] P. Cowen,et al. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers , 2005, Psychopharmacology.
[88] J. Gelernter,et al. Genetics of two μ opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects , 1999, Molecular Psychiatry.
[89] J. Sackellares,et al. Topiramate Titration and Tolerability , 2001, The Annals of pharmacotherapy.
[90] T. Feuerstein,et al. Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex—involvement of Na+/K+-ATPase , 2004, Neurochemistry International.
[91] D. Crommelin,et al. Controlled release of bioactive agents from lactide/glycolide polymers , 1990 .
[92] J. Rhodes,et al. Acute effects of Naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice , 2007, Psychopharmacology.
[93] R. Shank,et al. An Overview of the Preclinical Aspects of Topiramate: Pharmacology, Pharmacokinetics, and Mechanism of Action , 2000, Epilepsia.
[94] D. Davidson,et al. Ondansetron alters human alcohol intoxication , 1996, Biological Psychiatry.
[95] J. Stellar,et al. The Neurobiology of Motivation and Reward , 1985 .
[96] C. Naranjo,et al. The serotonin uptake inhibitor citalopram attenuates ethanol intake , 1987, Clinical pharmacology and therapeutics.
[97] S. Leucht,et al. Opioid antagonists for alcohol dependence. , 2010, The Cochrane database of systematic reviews.
[98] M. Davis,et al. Naltrexone blocks the post-shock increase of ethanol consumption. , 1986, Life sciences.
[99] M. Kornet,et al. Neuropeptides and alcohol addiction in monkeys. , 1994, EXS.
[100] J. McGeary,et al. Genetic moderators of naltrexone's effects on alcohol cue reactivity. , 2006, Alcoholism, clinical and experimental research.
[101] P. Cowen,et al. Alcohol‐induced reinforcement: Dopamine and 5‐HT3 receptor interactions in animals and humans , 1993 .
[102] G. Bell,et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. , 1994, Molecular pharmacology.
[103] J. Krystal,et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. , 2007, The American journal of psychiatry.
[104] G. Avanzini,et al. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. , 1999, The Journal of pharmacology and experimental therapeutics.
[105] Jennie Z Ma,et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial , 2003, The Lancet.
[106] S. Evans,et al. Acute effects of memantine in combination with alcohol in moderate drinkers , 2004, Psychopharmacology.
[107] J A Tischfield,et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[108] N. Ait-Daoud,et al. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings , 2000, Psychopharmacology.
[109] H. White,et al. Topiramate Modulates GABA‐Evoked Currents in Murine Cortical Neurons by a Nonbenzodiazepine Mechanism , 2000, Epilepsia.
[110] I. Geller. Effects of para-chlorophenylalanine and 5-hydroxytryptophan on alcohol intake in the rat. , 1973, Pharmacology, biochemistry, and behavior.
[111] S. Iversen,et al. Substance P analog, DiMe-C7: evidence for stability in rat brain and prolonged central actions. , 1982 .
[112] C. Heyser,et al. mu-Opioid receptor knockout mice do not self-administer alcohol. , 2000, The Journal of pharmacology and experimental therapeutics.
[113] Regat Seyoum,et al. GABAA and Opioid Receptors of the Central Nucleus of the Amygdala Selectively Regulate Ethanol-Maintained Behaviors , 2004, Neuropsychopharmacology.
[114] K. Mann,et al. Drugs for Relapse Prevention of Alcoholism , 2005 .
[115] D. Gorelick,et al. Effect of fluoxetine on alcohol consumption in male alcoholics. , 1992, Alcoholism, clinical and experimental research.
[116] M. Linnoila,et al. Family history of alcoholism in violent offenders and impulsive fire setters. , 1989, Archives of general psychiatry.
[117] K. Lynch,et al. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. , 2004, Alcoholism, clinical and experimental research.
[118] P. Lehert,et al. Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence? , 2003, Journal of psychopharmacology.
[119] T. Meert. Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. , 1993, Alcohol and alcoholism.
[120] J. Gelernter,et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. , 2006, Human molecular genetics.
[121] K. Mann,et al. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. , 2004, Alcoholism, clinical and experimental research.
[122] Rainer Spanagel,et al. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway , 1992 .
[123] A. Hansson,et al. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol‐seeking behavior in rats , 2005, The European journal of neuroscience.
[124] R. Spanagel,et al. Actions of Acamprosate on Neurons of the Central Nervous System , 1996 .
[125] B. Johnson. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. , 2004, Alcoholism, clinical and experimental research.
[126] P. de Witte,et al. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. , 1991, Alcohol and alcoholism.
[127] B. Basavarajappa,et al. Chronic Ethanol Increases the Cannabinoid Receptor Agonist Anandamide and Its Precursor N‐Arachidonoylphosphatidylethanolamine in SK ‐ N ‐ SH Cells , 1999, Journal of neurochemistry.
[128] G. Mittleman,et al. PRECLINICAL STUDY: Schedule‐induced alcohol drinking: non‐selective effects of acamprosate and naltrexone , 2006, Addiction biology.
[129] D. Couper,et al. Dose-Ranging Kinetics and Behavioral Pharmacology of Naltrexone and Acamprosate, Both Alone and Combined, in Alcohol-Dependent Subjects , 2003, Journal of clinical psychopharmacology.
[130] D. Filliol,et al. A Single Nucleotide Polymorphic Mutation in the Human μ-Opioid Receptor Severely Impairs Receptor Signaling* , 2001, The Journal of Biological Chemistry.
[131] M. Kreek,et al. Hypothalamic-Pituitary-Adrenocortical (HPA) Axis Response and Biotransformation of Oral Naltrexone: Preliminary Examination of Relationship to Family History of Alcoholism , 2002, Neuropsychopharmacology.
[132] D. Lovinger. Ethanol potentiates ion current mediated by 5-HT3 receptors on neuroblastoma cells and isolated neurons. , 1991, Alcohol and alcoholism (Oxford, Oxfordshire). Supplement.
[133] K. Mann,et al. Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry. , 2005, Alcoholism, clinical and experimental research.
[134] H. Kranzler,et al. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. , 2004, Alcoholism, clinical and experimental research.
[135] S. Evans,et al. A pilot double-blind treatment trial of memantine for alcohol dependence. , 2007, Alcoholism, clinical and experimental research.
[136] J. Nagy. Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? , 2004, IDrugs : the investigational drugs journal.
[137] N. W. Pedigo,et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. , 2002, Alcoholism, clinical and experimental research.
[138] H. Kranzler,et al. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. , 2001, Alcoholism, clinical and experimental research.
[139] David Couper,et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. , 2006, JAMA.
[140] C. Gottfries. Influence of depression and antidepressants on weight , 1981, Acta psychiatrica Scandinavica. Supplementum.
[141] R. Quirion,et al. A microdialysis profile of β-endorphin and catecholamines in the rat nucleus accumbens following alcohol administration , 2003, Psychopharmacology.
[142] A. Cnaan,et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. , 2000, Alcoholism, clinical and experimental research.
[143] L. Lumeng,et al. Naloxone attenuation of voluntary alcohol consumption. , 1987, Alcohol and alcoholism (Oxford, Oxfordshire). Supplement.
[144] M. Shive,et al. Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .
[145] J. Volpicelli,et al. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence , 1997, Psychopharmacology.
[146] H. Kranzler,et al. Ritanserin in the treatment of alcohol dependence – a multi-center clinical trial , 1996, Psychopharmacology.
[147] J. Littleton,et al. Neuroprotective and Abstinence-Promoting Effects of Acamprosate , 2005, CNS drugs.
[148] John P. Allen,et al. Advances in development of medications for alcoholism treatment , 1998, Psychopharmacology.
[149] M. Fantino. Role of sensory input in the control of food intake. , 1984, Journal of the autonomic nervous system.
[150] J. Volpicelli,et al. Effect of naltrexone on alcohol "high" in alcoholics. , 1995, The American journal of psychiatry.
[151] Yong-Kyu Lee,et al. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. , 2005, Alcohol and alcoholism.
[152] D. Lovinger. 5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic , 1999, Neurochemistry International.
[153] A. J. Bradbury,et al. Laterality of dopamine function and neuroleptic action in the amygdala in the rat , 1985, Neuropharmacology.
[154] H. Kranzler,et al. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. , 1996, Alcoholism, clinical and experimental research.
[155] C. Naranjo,et al. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol‐dependent drinkers , 1992, Clinical pharmacology and therapeutics.
[156] R. D. Myers,et al. Action of the 5-HT2A Antagonist Amperozide on Alcohol-Induced Poikilothermia in Rats , 1998, Pharmacology Biochemistry and Behavior.
[157] R. North,et al. Opioids excite dopamine neurons by hyperpolarization of local interneurons , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[158] J. Macher,et al. Central effects of acamprosate: Part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers , 1998, Psychiatry Research: Neuroimaging.
[159] P. Witte. Naloxone reduces alcohol intake in a free-choice procedure even when both drinking bottles contain saccharin sodium or quinine substances. , 1984 .
[160] W. Whelihan,et al. Naltrexone-induced alterations in human ethanol intoxication. , 1994, The American journal of psychiatry.
[161] J. Monterosso,et al. Predicting treatment response to naltrexone: the influence of craving and family history. , 2001, The American journal on addictions.
[162] Lei Wang,et al. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[163] Steven I. Dworkin,et al. Differences in extracellular dopamine concentrations in the nucleus accumbens during response-dependent and response-independent cocaine administration in the rat , 1997, Psychopharmacology.
[164] M. Rogawski,et al. Selective Antagonism of GluR5 Kainate-Receptor-Mediated Synaptic Currents by Topiramate in Rat Basolateral Amygdala Neurons , 2003, The Journal of Neuroscience.
[165] D. Oslin,et al. A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients , 2003, Neuropsychopharmacology.
[166] S. Brown,et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold , 1997, Epilepsy Research.
[167] W. Kostowski,et al. Evidence that the amygdala is involved in the inhibitory effects of 5-HT3 receptor antagonists on alcohol drinking in rats. , 1995, Alcohol.
[168] A. Belger,et al. Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism , 2006, Neuropsychopharmacology.
[169] R. Rosenheck,et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. , 2007, Alcoholism, clinical and experimental research.
[170] D. Labriola,et al. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. , 1997, Archives of general psychiatry.
[171] R. D. Myers,et al. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. , 1987, Alcohol.
[172] K. Perry,et al. The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. , 2001, European journal of pharmacology.
[173] E. Czarnecka,et al. Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone , 2006, Pharmacology Biochemistry and Behavior.
[174] D. R. Grady,et al. The subchronic effects of the TRH analog TA-0910 and bromocriptine on alcohol preference in alcohol-preferring rats: development of tolerance and cross-tolerance. , 1994, Alcoholism, clinical and experimental research.
[175] Bankole A Johnson,et al. New weapon to curb smoking: no more excuses to delay treatment. , 2006, Archives of internal medicine.
[176] E. Sellers,et al. Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure , 1995, Psychopharmacology.
[177] J. Durlach,et al. Lack of effects of Ca-acetyl homotaurinate on chronic and acute toxicities of ethanol in rats. , 1987, Alcohol.
[178] Ting-kai Li,et al. Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. , 1998, Critical reviews in neurobiology.
[179] L. Sobell,et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. , 1994, Alcoholism, clinical and experimental research.
[180] J. Roache,et al. Drug addiction and its treatment : nexus of neuroscience and behavior , 1997 .
[181] H. Kranzler,et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. , 2005, JAMA.
[182] R. D. Myers,et al. Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systemic cyanamide , 1992, Pharmacology Biochemistry and Behavior.
[183] F. Bloom,et al. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide , 2005, Psychopharmacology.
[184] T. Svensson,et al. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition , 2004, Psychopharmacology.
[185] J. Allen,et al. Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. , 1996, Alcoholism, clinical and experimental research.
[186] C. de Montigny,et al. Modification of 5‐HT neuron properties by sustained administration of the 5‐HT1A agonist gepirone: Electrophysiological studies in the rat brain , 1987, Synapse.
[187] J. Magnen,et al. Alcohol Aversion in the Rat: Behavioral Assessment of Noxious Drug Effects , 1970, Science.
[188] W. Mcbride,et al. Apomorphine and 7-OH DPAT reduce ethanol intake of P and HAD rats. , 1996, Alcohol.
[189] W. Brink,et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients , 2005, Psychopharmacology.
[190] H. de Wit,et al. Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers , 1995, Behavioural pharmacology.
[191] J. Farook,et al. Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. , 2007, Alcohol and alcoholism.
[192] S. Sombati,et al. Cellular Actions of Topiramate: Blockade of Kainate‐Evoked Inward Currents in Cultured Hippocampal Neurons , 2000, Epilepsia.
[193] B. Costall,et al. Effects of the 5‐HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain , 1987, British journal of pharmacology.
[194] R. Feinn,et al. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. , 2003, Alcoholism, clinical and experimental research.
[195] H. Samson,et al. Oral ethanol self-administration in the rat: Effect of naloxone , 1985, Pharmacology Biochemistry and Behavior.
[196] R. Wurtman,et al. Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats. , 1977, Science.
[197] R. J. Simpson,et al. Effect of zimelidine, a new antidepressant, on appetite and body weight. , 1981, British journal of clinical pharmacology.
[198] A. Alterman,et al. Naltrexone and alcohol dependence. Role of subject compliance. , 1997, Archives of general psychiatry.
[199] G. Gessa,et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence. , 2000, Alcoholism, clinical and experimental research.
[200] G. Gessa,et al. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. , 2005, Alcohol and alcoholism.
[201] Andrew D. Johnson,et al. Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G* , 2005, Journal of Biological Chemistry.
[202] B. Rounsaville,et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. , 2000, Addiction.
[203] P. Lehert,et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. , 2006, Journal of psychiatric research.
[204] F. Bruno. Buspirone in the treatment of alcoholic patients. , 1989, Psychopathology.
[205] R. Schreiber,et al. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats. , 1999, Alcohol.
[206] G. Gessa,et al. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats. , 2004, European journal of pharmacology.
[207] Jennie Z. Ma,et al. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. , 2004, Archives of general psychiatry.
[208] L. Heisler,et al. Reduction of Fat and Protein Intakes But Not Carbohydrate Intake Following Acute and Chronic Fluoxetine in Female Rats , 1999, Pharmacology Biochemistry and Behavior.
[209] D. Lovinger,et al. Alcohols potentiate ion current mediated by recombinant 5-HT3RA receptors expressed in a mammalian cell line , 1994, Neuropharmacology.
[210] L. Lumeng,et al. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference , 1990, Pharmacology Biochemistry and Behavior.
[211] G. Koob,et al. Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. , 1999, Zhongguo yao li xue bao = Acta pharmacologica Sinica.
[212] B. Johnson. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept--an hypothesis. , 2000, Alcoholism, clinical and experimental research.
[213] M. Branchey,et al. Age of alcoholism onset. I. Relationship to psychopathology. , 1989, Archives of general psychiatry.
[214] G. Gessa,et al. Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats. , 2004, European journal of pharmacology.
[215] S. Esteban,et al. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[216] C. Gianoulakis,et al. Implication of the endogenous opioid system in excessive ethanol consumption. , 1996, Alcohol.
[217] D. Naber,et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. , 2003, Archives of general psychiatry.
[218] W. Danysz,et al. N-methyl-D-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice , 2006, Behavioural pharmacology.
[219] M. Misawa,et al. Roles of 5-HT3 and opioid receptors in the ethanol-induced place preference in rats exposed to conditioned fear stress. , 1999, Life sciences.
[220] P. Jatlow,et al. Disulfiram effects on responses to intravenous cocaine administration. , 2007, Drug and alcohol dependence.
[221] J. Littleton,et al. Acamprosate in alcohol dependence: how does it work? , 1995, Addiction.
[222] R. Spanagel,et al. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. , 1997, Trends in pharmacological sciences.
[223] C. Naranjo,et al. Zimelidine‐induced variations in alcohol intake by nondepressed heavy drinkers , 1984, Clinical pharmacology and therapeutics.
[224] R. Swift. Drug therapy for alcohol dependence. , 1999, The New England journal of medicine.
[225] N. Grahame,et al. Ethanol oral self-administration is increased in mutant mice with decreased β-endorphin expression 1 Published on the World Wide Web on 1 April 1999. 1 , 1999, Brain Research.
[226] S. Schulz,et al. Effect of the A118G polymorphism on binding affinity, potency and agonist‐mediated endocytosis, desensitization, and resensitization of the human mu‐opioid receptor , 2004, Journal of neurochemistry.
[227] E. Sellers,et al. Serotonin and alcohol drinking. , 1992, NIDA research monograph.
[228] C. Cunningham,et al. Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice. , 2005, Alcoholism, clinical and experimental research.
[229] J. Kocsis,et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. , 1996, JAMA.
[230] J. Leander. Fluoxetine suppresses palatability-induced ingestion , 2004, Psychopharmacology.
[231] M. C. Ritz,et al. Selective serotonin reuptake inhibitors: effects of chronic treatment on ethanol-reinforced behavior in mice. , 1995, Alcohol.
[232] C. Hodge,et al. Specific decreases in ethanol- but not water-reinforced responding produced by the 5-HT3 antagonist ICS 205-930. , 1993, Alcohol.
[233] J. Macher,et al. Central effects of acamprosate: Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats , 1998, Psychiatry Research: Neuroimaging.
[234] M. Dongier,et al. Bromocriptine in the treatment of alcohol dependence. , 1991, Alcoholism, clinical and experimental research.
[235] T. Mueller,et al. Sertraline Treatment of Co-occurring Alcohol Dependence and Major Depression , 2006, Journal of clinical psychopharmacology.
[236] D. Lovinger,et al. Ethanol potentiation of 5-hydroxytryptamine3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. , 1991, Molecular pharmacology.
[237] F. Lallemand,et al. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. , 2006, Alcohol.
[238] C. Naranjo,et al. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers , 1990, Clinical pharmacology and therapeutics.
[239] R. D. Myers,et al. Alcohol Preference in the Rat: Reduction Following Depletion of Brain Serotonin , 1968, Science.
[240] B. Rounsaville,et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. , 2004, Archives of general psychiatry.
[241] R. Quirion,et al. An in vivo profile of β-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol , 2004, Neuroscience.
[242] M. Soyka. Acamprosate in Relapse Prevention of Alcoholism , 2011, Springer Berlin Heidelberg.
[243] E. Nickel,et al. A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. , 1995, Alcoholism, clinical and experimental research.
[244] R. Langer,et al. Biodegradable polymers as drug delivery systems , 1990 .
[245] David E. Smith,et al. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial , 2005, BMC psychiatry.
[246] K. Gill,et al. A further examination of the effects of sertraline on voluntary ethanol consumption. , 1988, Alcohol.
[247] W. Mcbride,et al. Serotonin and ethanol preference. , 1989, Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism.
[248] B. Ritson,et al. Disulfiram Treatment of Alcoholism , 1992, British Journal of Psychiatry.
[249] R. D. Myers,et al. Suppression of Alcohol Preference in High Alcohol Drinking Rats , 1996, Neuropsychopharmacology.
[250] R. Shank,et al. Topiramate as an Inhibitor of Carbonic Anhydrase Isoenzymes , 2000, Epilepsia.
[251] R. Anton,et al. Pharmacologic approaches to the management of alcoholism. , 2001, The Journal of clinical psychiatry.
[252] C. Heyser,et al. Effects of Naltrexone Alone and In Combination With Acamprosate on the Alcohol Deprivation Effect in Rats , 2003, Neuropsychopharmacology.
[253] J. Blundell,et al. Serotonin and appetite , 1984, Neuropharmacology.
[254] J. Stewart,et al. Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. , 1996, Archives of general psychiatry.
[255] G. Gessa,et al. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. , 2003, Drug and alcohol dependence.
[256] J. Juárez,et al. Alcohol consumption is enhanced after naltrexone treatment. , 2007, Alcoholism, clinical and experimental research.
[257] J. Solís,et al. Two new actions of topiramate: inhibition of depolarizing GABAA-mediated responses and activation of a potassium conductance , 2002, Neuropharmacology.
[258] C. Gianoulakis. Alcohol-seeking behavior: the roles of the hypothalamic-pituitary-adrenal axis and the endogenous opioid system. , 1998 .